Logopenic aphasia due to Lewy body disease dramatically improved with donepezil

Kazuo Kakinuma; Toru Baba; Michinori Ezura; Keiko Endo; Yumiko Saito; Wataru Narita; Osamu Iizuka; Yoshiyuki Nishio; Akio Kikuchi; Takafumi Hasegawa; Masashi Aoki; Kyoko Suzuki

doi:10.1016/j.ensci.2020.100241

Logopenic aphasia due to Lewy body disease dramatically improved with donepezil

eNeurologicalSci. 2020 May 8:19:100241. doi: 10.1016/j.ensci.2020.100241. eCollection 2020 Jun.

Authors

Affiliations

¹ Department of Behavioral Neurology and Cognitive Neuroscience, Tohoku University Graduate School of Medicine, Sendai, Japan.
² Department of Neurology, National Hospital Organization Sendai-Nishitaga Hospital, Sendai, Japan.
³ Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
⁴ Department of Rehabilitation, Tohoku University Hospital, Sendai, Japan.
⁵ Department of Psychiatry & Neurology, Tokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan.

Abstract

•Pathological basis of primary progressive aphasia is heterogeneous.•Logopenic primary progressive aphasia can precede dementia with Lewy bodies (DLB).•Cholinesterase inhibitor can improve logopenic aphasia with DLB.

Keywords: Alzheimer's disease; Cholinesterase inhibitor; Lewy body disease; Logopenic aphasia; Primary progressive aphasia.

Publication types

Case Reports